Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Elanco Animal Health Inc
Next earnings Aug 5, 2026 (before open) · consensus $0.27 EPS, $1.34B rev
Last earnings +13.9% on 2026-05-06
Growing animal-health franchise with 55% gross margins, but inconsistent GAAP profits and a heavy amortization/debt load.
Sources: SEC EDGAR (CIK 0001739104, latest 10-Q filed 2026-05-06) · EODHD · analysis by claude-code · as of 6/21/2026, 8:49:04 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
Elanco is a pure-play animal-health company with a solid product gross margin of 55.0% and renewed top-line momentum — FY2025 revenue grew 6.2% to $4.71B, the best growth in the five-year record after several flat years. Yet the company swung back to a GAAP net loss of -$232M (EPS -$0.47) from a +$338M profit in FY2024, leaving net margin at -4.9% and ROE at -3.5%. The five-year history is volatile: losses of -$483M, -$78M and -$1.23B (FY2021-FY2023), a single profitable year, and now another loss. Much of this reflects the heavy intangible amortization from its Bayer-era acquisition — depreciation and amortization of $680M dwarfs the reported loss, so cash earnings are meaningfully better than GAAP.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $4.76B | $4.41B | $4.42B | $4.44B | $4.71B |
| Gross profit | — | — | $2.49B | $2.44B | $2.59B |
| Operating income | — | — | — | — | — |
| Net income | -$483M | -$78.0M | -$1.23B | $338M | -$232M |
| Diluted EPS | -$0.99 | -$0.16 | -$2.50 | $0.68 | -$0.47 |
| Net margin | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1482 tracked peers · median
| 2026-05-21 | Scots-Knight Denise Director | Award | 4.68K | |
| 2026-05-21 | Scots-Knight Denise Director | Award | 12.2K | |
| 2026-05-21 | Kurzius Lawrence Erik Director | Award | 4.68K | |
| 2026-05-21 | Kurzius Lawrence Erik Director | Award | 12.2K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.